Boehringer Ingelheim will announce positive results from the landmark RE-COVERâ„¢ study at the 51st Annual Meeting of the American Society of Hematology on 6 December 2009. The RE-COVERâ„¢ study assessed dabigatran etexilate in a head-to-head comparison with the current standard in care, warfarin, for the treatment of acute venous thromboembolism (VTE), enabling healthcare professionals to make direct comparisons and care based value judgements.
More...